Get the Stockscreener App
88.99
0.63%
-0.56
After Hours:
88.30
-0.69
-0.78%
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca PLC stock is traded at $88.99, with a volume of 6.43M.
It is down -0.63% in the last 24 hours and up +5.08% over the past month.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
See More
Previous Close:
$89.55
Open:
$89.555
24h Volume:
6.43M
Relative Volume:
1.36
Market Cap:
$275.99B
Revenue:
$58.07B
Net Income/Loss:
$9.40B
P/E Ratio:
29.55
EPS:
3.0113
Net Cash Flow:
$8.49B
1W Performance:
+1.49%
1M Performance:
+5.08%
6M Performance:
+27.69%
1Y Performance:
+39.48%
1-Day Range:
$88.59
$90.06
1-Week Range:
$87.62
$90.27
52-Week Range:
$61.24
$90.27
Astrazeneca PLC Stock (AZN) Company Profile
Name
Astrazeneca PLC
Sector
Industry
Phone
44 20 3749 5000
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Compare AZN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
88.99 | 277.65B | 58.07B | 9.40B | 8.49B | 3.0113 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-27-25 | Resumed | Jefferies | Buy |
| Oct-16-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca PLC Stock (AZN) Latest News
Can Precidian ETFs Trust AstraZeneca PLC stock deliver double digit returnsMarket Sentiment Review & Long-Term Capital Growth Strategies - newser.com
How AstraZeneca PLC (Common Stock) (ZEGA) stock compares with top peers2025 Technical Patterns & Safe Capital Growth Trade Ideas - newser.com
Why AstraZeneca PLC (Common Stock) (ZEGA) stock is favored by hedge funds2025 Trading Recap & Fast Exit and Entry Strategy Plans - newser.com
What valuation multiples suggest for AstraZeneca PLC Depositary Receipt stock2025 Volume Leaders & Expert Curated Trade Ideas - newser.com
Will AstraZeneca PLC (Common Stock) (ZEGA) stock deliver compounding returnsJuly 2025 Trends & Free Low Drawdown Momentum Trade Ideas - newser.com
Will AstraZeneca PLC Depositary Receipt continue its uptrendShare Buyback & Verified Momentum Stock Ideas - newser.com
Using fundamentals and technicals on AstraZeneca PLC Depositary ReceiptEarnings Summary Report & Weekly Stock Performance Updates - newser.com
What insider trading reveals about AstraZeneca PLC Depositary Receipt stockEarnings Growth Report & Reliable Volume Spike Trade Alerts - newser.com
Can AstraZeneca PLC (Common Stock) (ZEGA) stock surprise with quarterly resultsJuly 2025 Momentum & Fast Gain Swing Alerts - newser.com
AstraZeneca Wins FDA Approval for Selumetinib in Adult NF1 Patients - MarketScreener
AstraZeneca (AZN) Gains FDA Approval for Koselugo in Neurofibrom - GuruFocus
AstraZeneca (AZN) Gains FDA Approval for Koselugo in Adult Treat - GuruFocus
AstraZeneca trades near highs after robust financials drive institutional flows - Traders Union
Is Precidian ETFs Trust AstraZeneca PLC stock safe for risk averse investorsRecession Risk & Daily Profit Maximizing Tips - newser.com
Will AstraZeneca PLC Depositary Receipt stock benefit from sector rotationPortfolio Update Report & Weekly Setup with High ROI Potential - newser.com
Is AstraZeneca PLC (ZEG) stock positioned for digital growth eraWeekly Stock Recap & Consistent Growth Equity Picks - newser.com
Will Precidian ETFs Trust AstraZeneca PLC stock deliver compounding returnsAnalyst Upgrade & Weekly High Conviction Ideas - newser.com
Is Precidian ETFs Trust AstraZeneca PLC stock a top dividend aristocrat candidateJuly 2025 Decliners & Fast Entry Momentum Alerts - newser.com
Is AstraZeneca PLC (ZEG) stock undervalued historicallyWeekly Profit Report & Community Driven Trade Alerts - newser.com
Published on: 2025-11-18 17:18:56 - newser.com
What market sentiment indicators show for Precidian ETFs Trust AstraZeneca PLC stock2025 AllTime Highs & Low Risk Growth Stock Ideas - newser.com
How AstraZeneca PLC (ZEG) stock trades under stagflationPortfolio Gains Summary & Risk Managed Investment Entry Signals - newser.com
AstraZeneca news: bullish momentum confirmed — strong support at Kijun GBX 12,949.00 - Traders Union
AstraZeneca Stock Hits Record High of $89.48 Amid Strong Q3 Performance - Somos Hermanos -
Will AstraZeneca PLC (ZEG) stock outperform small cap peersPortfolio Performance Summary & Consistent Growth Equity Picks - newser.com
Capital Group Increases Stake in AstraZeneca - TipRanks
AstraZeneca stock hits all-time high at 89.48 USD By Investing.com - Investing.com South Africa
REGAstraZeneca PLCHolding(s) in Company - TradingView
AstraZeneca stock hits all-time high at 89.48 USD - Investing.com
AstraZeneca price news: Overbought technicals warn of near-term reversal risk despite dominant buyer control - Traders Union
Has AstraZeneca PLC Depositary Receipt formed a bullish divergenceBull Run & Technical Pattern Based Signals - newser.com
Risk vs reward if holding onto AstraZeneca PLC Depositary ReceiptWeekly Stock Analysis & Short-Term Trading Alerts - newser.com
Is AstraZeneca PLC (Common Stock) (ZEGA) stock a top pick for value investors2025 Price Targets & High Return Stock Watch Alerts - newser.com
Technical signs of recovery in AstraZeneca PLC Depositary ReceiptWeekly Trading Summary & Fast Entry Momentum Trade Alerts - newser.com
Published on: 2025-11-15 09:27:21 - newser.com
Using Python tools to backtest AstraZeneca PLC Depositary Receipt strategiesWeekly Trend Summary & Long Hold Capital Preservation Tips - newser.com
Deutsche Bank Maintains ASTRAZENECA PLC(AZNCF.US) With Sell Rating, Raises Target Price to $138.06 - 富途牛牛
Astrazeneca PLC Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):